Palbociclib (PD-0332991) HCl Licensed by Pfizer

Catalog No.S1116

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Palbociclib (PD-0332991) HCl Chemical Structure

Palbociclib (PD-0332991) HCl Chemical Structure
Molecular Weight: 483.99

Validation & Quality Control

6 customer reviews :

Quality Control & MSDS

Related Compound Libraries

CDK Inhibitors with Unique Features

  • Pan CDK Inhibitor

    BAY 1000394 Pan-CDK1/2/3/4/7/9 inhibitor, IC50=5-25 nM.

  • Most Potent CDK Inhibitor

    LY2835219 CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Dinaciclib (SCH727965) Phase III for Chronic Lymphocytic Leukemia (CLL).

  • Newest CDK Inhibitor

    NU6027 Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Product Information

  • Compare CDK Inhibitors
    Compare CDK Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Targets CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
CDK2/CyclinE2 [1]
(Cell-free assay)

 View  More

IC50 9 nM 11 nM 15 nM >10 μM
In vitro PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MOLM13Ml\WT4lv[XOnIFHzd4F6MWiyOEBpNYjIRmhyUW6qaXLpeIlwdiCxZjDDSGs1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWmJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxOiEQvF2=MWqyOFY1OTFyMx?=
COLO205M3PsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnniO|IhcA>?MlXCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB|NjFOwG0>Mm\wNlQ3PDFzMEO=
U937MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWO3NkBpMYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvOTRizszNNGDh[nIzPDZ2MUGwNy=>
MOLM13MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDTc4E4OiCqMX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDoZZJjd3KrbnegSmxVOyCLVFSgcZV1[W62IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX|NJZXSqeX3p[Ilv\SCrboTvJGRPSSC5aYToJGlEPTBib3[gNE4xQTZizszNM3:yblI1PjRzMUCz
MOLM13NFu4TFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIO5ZZU4OiCqNHyzVZpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh|ryPNFjQW4ozPDZ2MUGwNy=>
MDA-MB-435MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3HTlAzPCCqNY\aW3VnUUN3ME2wMlE3KM7:TR?=M13Ve|E2QDBzOEOx
K562MV7DfZRwfG:6aXOgRZN{[Xl?NFryeVA6PiCqNUK3VGxLTE2VTx?=M3LWRmlEPTB;MjFOwG0>Mmm1NlQ1OTd3Nk[=
DU145M4f4SmN6fG:2b4jpZ{BCe3OjeR?=NYrxeWxDQTZiaB?=NYP3Woo{TE2VTx?=Mlq0TWM2OD15LkWg{txOMXKyOFQyPzV4Nh?=
MDA-MB-231MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWGxJO69VQ>?MnvuNlQhcA>?M2fGdWROW09?MkfSR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPlMXWyOFQyPzV4Nh?=
MCF7MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXvTJRMOSEQvF2=MYiyOEBpMU\EUXNQMme4R4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPlM4jVNVI1PDF5NU[2
MCF7NIDQTG1McW6jc3WgRZN{[Xl?NEm2bWI2KM7:TR?=MkH6NlQhcA>?NHrqWW1FVVORM2n1dmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC=M4TnSlI1PDF5NU[2
MDA-MB-231MYXLbY5ie2ViQYPzZZk>NFnpfG82KM7:TR?=NYHEXYNuOjRiaB?=MV7EUXNQMkSxTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?=NV2wNnl[OjR2MUe1OlY>
MDA-MB-231M2rFOGZ2dmO2aX;uJGF{e2G7NHLjcXYyNTFyIN88US=>MnHXNlQhcA>?NYficJRZTE2VTx?=MXHkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V?M4rSRVI1PDF5NU[2
MCF7M4nROWZ2dmO2aX;uJGF{e2G7M{[wdVEuOTBizszNNH3YXpgzPCCqMnHKSG1UVw>?NHOxemNld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W=NFXBNJczPDRzN{W2Oi=>
MDA-MB-231MVvGeY5kfGmxbjDBd5NigQ>?NWnV[Iw{OC53LUGg{txOM{[zN|Q5KGh?MmLoSG1UVw>?MonDbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U>NXfiR3UyOjR2MUe1OlY>
MCF7M3;IVGZ2dmO2aX;uJGF{e2G7M2jk[FAvPS1zIN88US=>NF7oe|Y1QCCqM3T1Z2ROW09?MUToZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=>M33ldVI1PDF5NU[2
697NV;zXItuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2n6fWlEPTB;MUS4MlM5KG6PM1nJXXNCVkeHUh?=
P12-ICHIKAWAM2C0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTl4LkC0JI5ONUnHVno5W0GQR1XS
NB69NUL2OFk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjKTYlKSzVyPUG2NU45KG6PNW\HWYg5W0GQR1XS
EoL-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvvb3k3UUN3ME2xPFcvOjZibl2=NYHSUGtvW0GQR1XS
BHT-101MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\pW3pKSzVyPUG5PE4zPSCwTR?=MVjTRW5ITVJ?
SK-NEP-1NFGxdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTJ{MD6wNkBvVQ>?MV3TRW5ITVJ?
MHH-NB-11M4PDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XUNGlEPTB;MkKwMlE6KG6PNV35XnI1W0GQR1XS
AsPC-1M1\vb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1m5bGlEPTB;MkWyMlU{KG6PMW\TRW5ITVJ?
ES1NIL5c2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\kWZhKSzVyPUK1Ok4zPSCwTR?=MX;TRW5ITVJ?
LAMA-84NYPqbJhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PQe2lEPTB;MkW4MlE6KG6PM2[5eXNCVkeHUh?=
MOLT-16NXHMcWJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDNSmhnUUN3ME2yOVgvPDlibl2=MnrsV2FPT0WU
ES7Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHjT3ZzUUN3ME2yO|MvODlibl2=M37KfnNCVkeHUh?=
KY821MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DBVWlEPTB;M{G0MlEhdk1?NVnLcIFvW0GQR1XS
RT-112NXLRfnNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nqRmlEPTB;M{KxMlA2KG6PNXf1SIhxW0GQR1XS
HL-60NUDwZXVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DxbWlEPTB;M{SwMlY3KG6PNGW2TGxUSU6JRWK=
MOLT-4MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF:2ZoVKSzVyPUO0OU4yOyCwTR?=MlnxV2FPT0WU
KARPAS-45NGCyXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTN5Nj6xOkBvVQ>?NFHsd4JUSU6JRWK=
SK-N-ASMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPORod5UUN3ME2zPFcvQDNibl2=NIT6d2RUSU6JRWK=
CTB-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1S0ZWlEPTB;NEC1MlAzKG6PMUfTRW5ITVJ?
NKM-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnO3TWM2OD12MUGuPFkhdk1?MkLtV2FPT0WU
HTC-C3M3fKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHVToxKUUN3ME20N|IvQTVibl2=MXjTRW5ITVJ?
BE-13MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrBN5JKSzVyPUS0OE4zPyCwTR?=MoXnV2FPT0WU
KOSC-2M3TrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1v4b2lEPTB;NE[2Mlkhdk1?MmDSV2FPT0WU
NB14MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHsOllrUUN3ME20PFMvPThibl2=MlzlV2FPT0WU
CAL-27NYPGU29rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnnUYp{UUN3ME20PVQvPTlibl2=MlzmV2FPT0WU
H9NFnGRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2ro[GlEPTB;NEm1MlQ{KG6PM3Tze3NCVkeHUh?=
RS4-11NGHBWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\qOWlEPTB;NUC0Mlc{KG6PM3LtNXNCVkeHUh?=
PA-1M3LsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVz5RoFjUUN3ME21NFkvQDZibl2=MkTTV2FPT0WU
MV-4-11MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDNTWM2OD13MUOuPFUhdk1?NGPhPIRUSU6JRWK=
OS-RC-2NHLpcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTV{MT62NkBvVQ>?M3\ibnNCVkeHUh?=
RPMI-8226MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nQcmlEPTB;NUK2Mlg3KG6PM2jEW3NCVkeHUh?=
HGC-27MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTV4ND65PUBvVQ>?MkjlV2FPT0WU
CHP-212NIO2fnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnXUVh6UUN3ME21PVMvPTlibl2=M2Dmd3NCVkeHUh?=
NB10NHfSe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTV7OT6xPEBvVQ>?MlnDV2FPT0WU
HHM4PPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLTfJZmUUN3ME21PVkvPDNibl2=NVPPdnhlW0GQR1XS
EW-16MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTZyMz61NkBvVQ>?MonnV2FPT0WU
ES8NEfDe|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrsVZlYUUN3ME22NFUvOjFibl2=NYPJSGozW0GQR1XS
HAL-01M2jNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTZyNT62O{BvVQ>?MUTTRW5ITVJ?
A204MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrwOGt[UUN3ME22N|MvQTFibl2=MYTTRW5ITVJ?
MHH-PREB-1NEW2b|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPPTWM2OD14M{[uPVkhdk1?MnnaV2FPT0WU
EM-2NF61enVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\WOW1KSzVyPU[1NE43PCCwTR?=M{\KbXNCVkeHUh?=
BV-173M4O1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTZ3Mj60PEBvVQ>?MoLIV2FPT0WU
ONS-76MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXMR3dWUUN3ME22O|cvQDJibl2=NGHJfJNUSU6JRWK=
KM-H2NHPLeVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHwTWM2OD14OUWuOVQhdk1?M{T3b3NCVkeHUh?=
D-263MGM4LT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\kXllyUUN3ME23NVcvOTJibl2=MWnTRW5ITVJ?
ES3M1TFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk[3TWM2OD15MkiuPVMhdk1?Mlj6V2FPT0WU
VA-ES-BJNHu3UW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rNfWlEPTB;N{OyMlI4KG6PM3Gzd3NCVkeHUh?=
NBsusSRM2\WfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTd2Mj65PUBvVQ>?MYTTRW5ITVJ?
NCI-H520NHvBVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTd2Nj61NkBvVQ>?M1zQ[XNCVkeHUh?=
ES5M2DqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjOVIxKSzVyPUe1Nk45KG6PNHKxd4lUSU6JRWK=
T-24NFTvUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPZTWM2OD15N{iuO|Ehdk1?MnTEV2FPT0WU
SW962NVHtRlZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTBTWM2OD16MEiuOlMhdk1?MXPTRW5ITVJ?
EW-3NH;tdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XaSWlEPTB;OEC4Mlc3KG6PM{X6fHNCVkeHUh?=
RXF393M{DCV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrSbIRKSzVyPUixNk44QSCwTR?=MVzTRW5ITVJ?
U251NXfDbYl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3S5TGlEPTB;OEGzMlg5KG6PM2DEWnNCVkeHUh?=
CAMA-1NYfTUJVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTh|Mz65OEBvVQ>?NFrDT2RUSU6JRWK=
JVM-3NV61e3JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DzTmlEPTB;OEWxMlc5KG6PMUDTRW5ITVJ?
COLO-800M{Xvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTh7Nz63PEBvVQ>?M1XXWXNCVkeHUh?=
OVCAR-5MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zxNGlEPTB;OUCwMlEhdk1?MUPTRW5ITVJ?
LB1047-RCCNYPvc|ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHraUoRKSzVyPUmyO{42PiCwTR?=NHnoTXpUSU6JRWK=
SW954MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfUNmVNUUN3ME25NlkvPDFibl2=NUjxTVdvW0GQR1XS
J-RT3-T3-5NW\0VmVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXO1[2hHUUN3ME25N|YvODZibl2=NHnnTZlUSU6JRWK=
MewoMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHnW2JOUUN3ME25N|YvPiCwTR?=MYLTRW5ITVJ?
NCI-H1770MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlj3TWM2OD17NECuOVUhdk1?MW\TRW5ITVJ?
HO-1-N-1NHLhWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3Pm[2lEPTB;OU[yMlgyKG6PM1PHPXNCVkeHUh?=
HSC-3MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvWO2JOUUN3ME25OlYvPDhibl2=Mn3MV2FPT0WU
TYK-nuNVn2T4tbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTl7OD6yOUBvVQ>?MVzTRW5ITVJ?
KYSE-150MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTFwMECwO|Yh|ryPNWDucWRoW0GQR1XS
SN12CM3f5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrGSYJKSzVyPUGuNFA5PzVizszNMoX5V2FPT0WU
MOLT-13MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTFwMEG0NlEh|ryPNXjVflNtW0GQR1XS
TE-11MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTFwMES4NVIh|ryPNFezbZpUSU6JRWK=
DBNHriNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYm2cGRHUUN3ME2xMlA4Ojd|IN88US=>M1vISXNCVkeHUh?=
CAL-39M4OybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmX3TWM2OD1zLkC3OVIzKM7:TR?=M3TX[3NCVkeHUh?=
A3-KAWMornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLDWmhKSzVyPUGuNFg1ODhizszNMnfJV2FPT0WU
CHP-134NH[wUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTFwMUG4NFch|ryPM4r6THNCVkeHUh?=
TGWNX;LboJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInue|lKSzVyPUGuNVI{QTVizszNMV7TRW5ITVJ?
QIMR-WILMnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HqcmlEPTB;MT6xN|E{PCEQvF2=NGfq[VhUSU6JRWK=
NCI-SNU-1NHHzWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHFTWM2OD1zLkG2N|U1KM7:TR?=NHXZTItUSU6JRWK=
CGTH-W-1M1H0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTFwMUexPFYh|ryPNXSzVZJxW0GQR1XS
MHH-ES-1MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTFwMUe5PFYh|ryPMXrTRW5ITVJ?
LB2241-RCCM2\mUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrUd3hVUUN3ME2xMlE5PjJizszNMYXTRW5ITVJ?
ML-2M1nzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTFwMkC3N|Qh|ryPNEC0U3BUSU6JRWK=
COR-L23NUGxN2R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvt[olKSzVyPUGuNlI6OzNizszNNGHFbG9USU6JRWK=
BFTC-905MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXwTWM2OD1zLkK0NlY4KM7:TR?=NYW4UHlLW0GQR1XS
Hs-578-TM3Xy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3e5VGlEPTB;MT6yOVgyPyEQvF2=MkLoV2FPT0WU
KG-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTFwMk[2PFYh|ryPNYnkcFNQW0GQR1XS
HELMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWX6[GZEUUN3ME2xMlI6OzN6IN88US=>NHjDOnNUSU6JRWK=
A549MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\L[WRmUUN3ME2xMlI6Ozl7IN88US=>NHjKbmFUSU6JRWK=
COLO-741M3H0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;uTWM2OD1zLkOyNFg6KM7:TR?=M1;OdHNCVkeHUh?=
PC-3MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXH6VWpWUUN3ME2xMlM2OjJzIN88US=>MU\TRW5ITVJ?
HOSNFPGToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHThb21KSzVyPUGuN|UzQTZizszNNInVSHRUSU6JRWK=
HT-1080M1zJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfTTWM2OD1zLkO3OVE6KM7:TR?=MUHTRW5ITVJ?
TE-8MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTFwNEG3O|Qh|ryPM1vNN3NCVkeHUh?=
BHYMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmm4TWM2OD1zLkS2PVI{KM7:TR?=MmDoV2FPT0WU
BB65-RCCMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFKyNnFKSzVyPUGuOVA2OjhizszNM{LnXHNCVkeHUh?=
HNMkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjhTWM2OD1zLkW0NFcyKM7:TR?=NUHyWIZEW0GQR1XS
NCI-H441MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3r6[GlEPTB;MT61OFkxPyEQvF2=NIG3bJNUSU6JRWK=
RPMI-8866MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTFwNUi1NFch|ryPNHvUUphUSU6JRWK=
CAL-62NGHTfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrZTWM2OD1zLk[wPFYzKM7:TR?=NFmzbW1USU6JRWK=
MG-63MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7RS41KSzVyPUGuOlE5OTNizszNNF7JZW1USU6JRWK=
SK-LU-1MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLWcGdiUUN3ME2xMlYzOTV{IN88US=>MUjTRW5ITVJ?
BCPAPMl;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTFwNk[0OVch|ryPNUnLOFByW0GQR1XS
22RV1Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\HZnpKSzVyPUGuOlc5PDNizszNNIeyfVBUSU6JRWK=
T47DNU[5XmRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHSS|ZMUUN3ME2xMlY5ODZzIN88US=>M17MNXNCVkeHUh?=
MSTO-211HM2DVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLEOXExUUN3ME2xMlY6PjB|IN88US=>M{mw[3NCVkeHUh?=
DELMl:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTFwN{CyO|Mh|ryPNVP1WmNLW0GQR1XS
H4NFLRT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTFwN{OyNVIh|ryPM1XiOHNCVkeHUh?=
CAL-51M2fIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPIRYR4UUN3ME2xMlc1QDV3IN88US=>NYHhcW1XW0GQR1XS
ABC-1M2LaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTFwN{i1PFIh|ryPMXLTRW5ITVJ?
MZ2-MELNFTvdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\0UWlEPTB;MT63PVU1OiEQvF2=NV7Dd5NEW0GQR1XS
YKG-1MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfXTWM2OD1zLkixNFYyKM7:TR?=MniyV2FPT0WU
KM12NEHoZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTFwOEG2NFIh|ryPNHrLe2JUSU6JRWK=
L-363NUXJVWhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlztTWM2OD1zLki3OFEzKM7:TR?=NGXhSphUSU6JRWK=
KU812NVL4Vol6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYH1N4FrUUN3ME2xMlg6Ojh{IN88US=>NVv4cnFtW0GQR1XS
LOXIMVIM1;yZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTFwOUGyNlgh|ryPMk\UV2FPT0WU
G-401NH\aRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\wdGpKSzVyPUGuPVI1OjhizszNNEnk[GpUSU6JRWK=
SW780NGDrVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLTNWtrUUN3ME2xMlk3OjR4IN88US=>Mn\OV2FPT0WU
SW872NIDKe3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjGTWM2OD1zLkm4N|Mh|ryPNUm2T4FUW0GQR1XS
NB7NWmybZVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITBUYZKSzVyPUGuPVk{OjNizszNNHfsR3BUSU6JRWK=
T98GNUewcHl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfCZ|JKSzVyPUKuNFA3PjZizszNM4DibnNCVkeHUh?=
SW1710MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfwVGo1UUN3ME2yMlA3QTR3IN88US=>NYLieHlCW0GQR1XS
NCI-H1573MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTJwMEeyPVgh|ryPM4rDcXNCVkeHUh?=
KE-37MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTJwMEi5OVEh|ryPM1XxWHNCVkeHUh?=
786-0M3XINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3YTWM2OD1{LkG1OFM6KM7:TR?=M3nwdXNCVkeHUh?=
SASMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXRdYh[UUN3ME2yMlIxOzd2IN88US=>NUnLfGJIW0GQR1XS
CAL-54NFi5TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTJwMkC0NVMh|ryPNFvOSolUSU6JRWK=
SF268M3LsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1L4[mlEPTB;Mj6yN|EzOiEQvF2=M17SOHNCVkeHUh?=
SW620MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDhTWM2OD1{LkK2NVY6KM7:TR?=M33PN3NCVkeHUh?=
MN-60NVizdogxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTJwM{GwOkDPxE1?NULST3hnW0GQR1XS
EFO-27MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTCfFNKSzVyPUKuN|IxPThizszNNU[wZnppW0GQR1XS
NCI-H747M{jFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX2zbmNPUUN3ME2yMlMzOTl7IN88US=>MYnTRW5ITVJ?
HCC2218Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\EcpRKUUN3ME2yMlM2Ozd2IN88US=>M3XyRXNCVkeHUh?=
MIA-PaCa-2MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFj5TIhKSzVyPUKuN|Y1OzdizszNMW\TRW5ITVJ?
SJSA-1NY[3fHJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTJwM{e3PVYh|ryPNWjXVWF5W0GQR1XS
RKONXrwOJk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTJwM{i0PVYh|ryPNUjuPYc3W0GQR1XS
NB6M{O2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jZSmlEPTB;Mj60NFM4PCEQvF2=NXy0PJF{W0GQR1XS
ES4NVnrVYxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTJwNEW0NlIh|ryPMm\wV2FPT0WU
EGI-1NIrEepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETMXGlKSzVyPUKuOFY5QDNizszNMorOV2FPT0WU
CTV-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLCWHVMUUN3ME2yMlUzPzd|IN88US=>M17IUHNCVkeHUh?=
NCI-H1355MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHR[WlKSzVyPUKuOVU6PTFizszNNVHQUmNqW0GQR1XS
GT3TKBMm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTHTWM2OD1{LkW5NVk6KM7:TR?=M{XY[HNCVkeHUh?=
SK-HEP-1M2KxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTJwNUmyOlYh|ryPMoDhV2FPT0WU
GAMGMlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jabGlEPTB;Mj61PVM6PCEQvF2=M3LDWnNCVkeHUh?=
SK-MES-1M4G4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFu3U2FKSzVyPUKuOlE5ODNizszNMmi1V2FPT0WU
RO82-W-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M335SmlEPTB;Mj62NlA2PyEQvF2=MX3TRW5ITVJ?
ECC10NIXxSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXvUWY3UUN3ME2yMlcxOjB4IN88US=>MVnTRW5ITVJ?
MCF7NWn2RW8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPFTWM2OD1{LkexOFY1KM7:TR?=MV7TRW5ITVJ?
D-283MEDM3OyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTJwN{K0N{DPxE1?NXPn[Fd{W0GQR1XS
RPMI-7951M3rqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3z[IV5UUN3ME2yMlc2Pjl2IN88US=>NVrVVVhGW0GQR1XS
Ramos-2G6-4C10NGrObItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;tN5FqUUN3ME2yMlc4ODl7IN88US=>NF6wO|FUSU6JRWK=
KGNM2Dncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnNT3RWUUN3ME2yMlgyQDh2IN88US=>M3TqOnNCVkeHUh?=
NUGC-3NYiyPWFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTJwOEK1NFUh|ryPMoe3V2FPT0WU
NCI-H292NWjTSHlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjo[mJKSzVyPUKuPFUxPTNizszNM2TZenNCVkeHUh?=
BeckerM333XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTJwOUW4N|Ih|ryPNX\nZm1YW0GQR1XS
NCI-H1299M4TSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXL5WG5mUUN3ME2zMlA2OjZ|IN88US=>MVzTRW5ITVJ?
ETK-1M1jobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HzWGlEPTB;Mz6wOVQ{KM7:TR?=MmTTV2FPT0WU
TK10MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnSwTWM2OD1|LkKwNVY2KM7:TR?=MmTkV2FPT0WU
VMRC-RCZMlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzvXJFKSzVyPUOuN|Y1QDhizszNNYmxW21QW0GQR1XS
YH-13MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTNwNESwO|kh|ryPNE\I[lFUSU6JRWK=
DU-145MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPoOopxUUN3ME2zMlQ3OjZ7IN88US=>MW\TRW5ITVJ?
SW1088NVHhNo9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTNwNEe0O{DPxE1?NWP3Oml5W0GQR1XS
HOP-92MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTNwNUCzOFIh|ryPMl3qV2FPT0WU
KP-N-YSNF\id|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjVTHFKSzVyPUOuOlIyOzlizszNMWjTRW5ITVJ?
NCI-H460NHvDXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XJUGlEPTB;Mz62Olc{KM7:TR?=NVzNR3E1W0GQR1XS
U-2-OSM{DveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLFN4NKSzVyPUOuO|I2OzVizszNNYjSeWZyW0GQR1XS
A101DNWi4cYZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jFc2lEPTB;Mz63Olk{PiEQvF2=NILtb|JUSU6JRWK=
MDA-MB-231NGPQNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTNwOEG5OVEh|ryPMnT2V2FPT0WU
IST-MES1M3PyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1znOGlEPTB;Mz64N|Ih|ryPNVjXZ5dLW0GQR1XS
COR-L105MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTJc2tKSzVyPUSuNFE5KM7:TR?=NYW1OZBqW0GQR1XS
NCI-H1437M{Wzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkK0TWM2OD12LkCyN|AzKM7:TR?=M1nDfXNCVkeHUh?=
CAL-85-1NXS5cHZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn76TWM2OD12LkCyOFYyKM7:TR?=MYDTRW5ITVJ?
MZ1-PCNVjWdpJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTRwMUi1OVYh|ryPM{P2dnNCVkeHUh?=
VM-CUB-1MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXYfHQ4UUN3ME20MlMyOjh2IN88US=>MVnTRW5ITVJ?
CHL-1NWHETVJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfqUJJKSzVyPUSuN|IyPjlizszNM3j0TXNCVkeHUh?=
MDA-MB-361MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDXTWM2OD12LkOzNVU{KM7:TR?=MknGV2FPT0WU
NCI-H661MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jE[2lEPTB;ND61NFA6OiEQvF2=MWfTRW5ITVJ?
EW-11NGHDbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7vTZpPUUN3ME20MlUzOjNzIN88US=>Moq5V2FPT0WU
BENM{PHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\lOVNKSzVyPUSuOVI5OTVizszNM{jYcXNCVkeHUh?=
BFTC-909MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIT6cY9KSzVyPUSuOVYzPzVizszNMofIV2FPT0WU
NCI-H2087NHHEXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLsTWM2OD12LkW4NVY1KM7:TR?=MUnTRW5ITVJ?
RVH-421NHHyNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPPPHpWUUN3ME20MlY3PjlizszNNFzrbIdUSU6JRWK=
P30-OHKNHvmW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTRwNkiwNFgh|ryPMXfTRW5ITVJ?
NCI-H28NXO3fJJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWO0TYUxUUN3ME20MlgyPjZzIN88US=>NHXIclVUSU6JRWK=
ES6NEPHeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW[3SnlDUUN3ME20Mlg{ODF4IN88US=>MXPTRW5ITVJ?
769-PM3;0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTRwOEW5NlYh|ryPM3n2cnNCVkeHUh?=
OE33NFLaTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTuTWM2OD12Lki4NVYyKM7:TR?=MUfTRW5ITVJ?
SW982NXfmUFdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTGSpY3UUN3ME20Mlk2ODZzIN88US=>NUnleo85W0GQR1XS
A388NFi0UpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTVwMEK5PFMh|ryPNELyN3dUSU6JRWK=
TI-73MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3TTWM2OD13LkC2NVk1KM7:TR?=NV\n[5NvW0GQR1XS
HCT-116MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjITWM2OD13LkC5PFg6KM7:TR?=MmThV2FPT0WU
HuP-T3NGnSNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvwTWM2OD13LkG4O|A6KM7:TR?=MUjTRW5ITVJ?
G-402NGPWdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7veYZKSzVyPUWuNVk1OTZizszNMny2V2FPT0WU
NCI-H1792Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTOTWM2OD13LkK0OlIzKM7:TR?=NXrxcos3W0GQR1XS
NCI-H209NIDWdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTlZ4hKSzVyPUWuNlU6PDJizszNMn7wV2FPT0WU
NCI-H1650MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTGTWM2OD13LkOwOlM1KM7:TR?=NYLHdXhEW0GQR1XS
LCLC-97TM1NWXGWpl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWm2PI1zUUN3ME21MlMyQDB6IN88US=>NIXv[I9USU6JRWK=
S-117Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfFTIlKSzVyPUWuN|Y6PzZizszNMWTTRW5ITVJ?
GI-ME-NNVLwXoVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;xNlk1UUN3ME21MlM6PjhzIN88US=>NVrTc2FCW0GQR1XS
NCI-H2122M4HNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkD2TWM2OD13LkS5N|k4KM7:TR?=M{nybXNCVkeHUh?=
NCI-H1793MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTVwNke1PVMh|ryPMVzTRW5ITVJ?
C2BBe1NWfDdnJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7CfIlUUUN3ME21MlcxODh6IN88US=>M2nYOHNCVkeHUh?=
TE-12MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfoTWM2OD13LkiwOVU3KM7:TR?=M4L4fXNCVkeHUh?=
LCLC-103HMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1L2fWlEPTB;NT65NVch|ryPMX7TRW5ITVJ?
A673NGLtcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTVwOUG5N|Ih|ryPM17mR3NCVkeHUh?=
BB30-HNCMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;sTWM2OD13Lkm4N|Yh|ryPM3XrWHNCVkeHUh?=
SF295MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjVdZlKSzVyPU[uNFA1OjJizszNNH3jN3NUSU6JRWK=
KU-19-19NEjYZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTZwMEG3N|Eh|ryPM3[4fHNCVkeHUh?=
CFPAC-1NIHmVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTZwMES0OFMh|ryPM3:0[nNCVkeHUh?=
LoVoM1f2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mkm2TWM2OD14LkC1NFY{KM7:TR?=MXnTRW5ITVJ?
8505CNF3iRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\jTWM2OD14LkC3OVc{KM7:TR?=NV\nbGxtW0GQR1XS
GMS-10MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkL5TWM2OD14LkG1NFAzKM7:TR?=NXHGTotnW0GQR1XS
Ca9-22MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVqyfnZvUUN3ME22MlE3PzFizszNMX;TRW5ITVJ?
DOKMkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTZwMkKwO|Ih|ryPMXrTRW5ITVJ?
FADUM2LX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4r0bGlEPTB;Nj6yOlA{QSEQvF2=MlfGV2FPT0WU
BxPC-3MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\HTWM2OD14LkK3N|Ih|ryPM4LIdXNCVkeHUh?=
CAL-33MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfIR3pxUUN3ME22MlI6OjBzIN88US=>MoLKV2FPT0WU
SHP-77NXPUTWs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fHPWlEPTB;Nj6zNVUyOiEQvF2=NGT0blJUSU6JRWK=
LXF-289MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlG0TWM2OD14LkOzOFU2KM7:TR?=M1jNfXNCVkeHUh?=
GB-1NF3tdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3S2SGlEPTB;Nj6zPFIh|ryPNIXSd|FUSU6JRWK=
KS-1NFvIV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4TSdGlEPTB;Nj6zPFQ1PyEQvF2=NV;VNYs{W0GQR1XS
D-502MGMmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTNTWM2OD14LkSyN|c3KM7:TR?=MVXTRW5ITVJ?
LAN-6Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{j1OGlEPTB;Nj61NVAzOyEQvF2=M4PFd3NCVkeHUh?=
H-EMC-SSNHnhWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTZwNU[xOFch|ryPMkTWV2FPT0WU
LC-2-adNXHzO5d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHFSpVtUUN3ME22MlYxODd4IN88US=>M3;sZnNCVkeHUh?=
NCI-H1693MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fvW2lEPTB;Nj62NlIyPSEQvF2=MUPTRW5ITVJ?
SK-N-FIM1;VOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTneIw5UUN3ME22Mlc2ODR2IN88US=>Mnj6V2FPT0WU
D-423MGMkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnvTWM2OD14Lke2NVE4KM7:TR?=M2fsb3NCVkeHUh?=
KNS-42NYnxXY97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTZwN{ixPVch|ryPM{DIVnNCVkeHUh?=
GCTMoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTZwOUO4JO69VQ>?NULvUJpZW0GQR1XS
DSH1MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\RTXVKSzVyPUeuNFY{OyEQvF2=NX\BV4gzW0GQR1XS
D-247MGMnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvOdYlKSzVyPUeuNFc5QDFizszNMYjTRW5ITVJ?
NCI-SNU-5M2nwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHlRZFKSzVyPUeuNVg{PzFizszNMnjqV2FPT0WU
TE-6MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlGxTWM2OD15LkKwOlAyKM7:TR?=NIDRSJpUSU6JRWK=
NOMO-1Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvuVHRKSzVyPUeuNlIyOjdizszNNUPBfGs3W0GQR1XS
NB17MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIO0bWNKSzVyPUeuN|A{ODlizszNNUHEcI1XW0GQR1XS
EW-22M3qwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknFTWM2OD15LkO0N|Q5KM7:TR?=MnSwV2FPT0WU
EW-13M33SXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HBdWlEPTB;Nz6zOVE3OiEQvF2=M{P4UnNCVkeHUh?=
DOHH-2Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTdwNESwNkDPxE1?MUTTRW5ITVJ?
TGBC1TKBMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTpPHp4UUN3ME23MlQ6QDl7IN88US=>NUDoVY9pW0GQR1XS
GR-STNHnLbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLFeI5KSzVyPUeuOVI2QTRizszNM{LHd3NCVkeHUh?=
KYSE-520NY\3dW1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnX3TWM2OD15LkW1OVE2KM7:TR?=NFvhbohUSU6JRWK=
CAPAN-1MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2q3U2lEPTB;Nz61PVUyKM7:TR?=M4\GWnNCVkeHUh?=
HCE-4M4XBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDYTWM2OD15Lk[yNlc6KM7:TR?=MkTQV2FPT0WU
MLMAMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTdwNkK5OVch|ryPNYLtNo86W0GQR1XS
HT-144MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NICxWXJKSzVyPUeuOlU{PjhizszNM2WxUHNCVkeHUh?=
KYSE-180MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\ne2lEPTB;Nz63NVE3QSEQvF2=MYrTRW5ITVJ?
TE-5MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXryOZJ[UUN3ME23Mlk2QTdzIN88US=>NUfm[pdMW0GQR1XS
IGROV-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUe3O5BpUUN3ME23Mlk5PTVzIN88US=>M2e1bXNCVkeHUh?=
NCI-H1581M2fHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRThwMEGyJO69VQ>?NVzOd5BiW0GQR1XS
SW1990Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;XTWM2OD16LkC0OlU6KM7:TR?=M1\weXNCVkeHUh?=
EFM-19NGrKWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DrOGlEPTB;OD6wPFU1PSEQvF2=MXfTRW5ITVJ?
OGR-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFGweIJKSzVyPUiuOFMxOjNizszNNF7IdpRUSU6JRWK=
U-118-MGNFH5OYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlj5TWM2OD16LkSzOFY{KM7:TR?=MnjXV2FPT0WU
SK-OV-3M2W4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWrzVHp7UUN3ME24MlQ3PzZ3IN88US=>NWLkU|NJW0GQR1XS
KNS-62M3nrbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknUTWM2OD16LkWxO|YyKM7:TR?=NXPwdFBRW0GQR1XS
GOTOMni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELwWINKSzVyPUiuOVc3OzVizszNMm\aV2FPT0WU
8305CNHvUfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRThwN{C0PFQh|ryPMl;qV2FPT0WU
RPMI-2650NFTBd4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLCTIt3UUN3ME24MlcyQTV3IN88US=>M3;KfnNCVkeHUh?=
NEC8MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRThwN{SzNFch|ryPNEHQZXdUSU6JRWK=
KYSE-450NGfrO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRThwOE[1OFgh|ryPMoC2V2FPT0WU
RMG-IM33oN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjMPIJXUUN3ME25MlE1ODV6IN88US=>MlXXV2FPT0WU
CAKI-1NWrzcWdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M131UmlEPTB;OT6zNVk4QSEQvF2=NUfGVFh2W0GQR1XS
KYSE-510NIXV[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWSyfI15UUN3ME25MlM2Pzd6IN88US=>NGLHWIZUSU6JRWK=
A4-FukNIrUe4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXG3PGRLUUN3ME25MlM3PzBzIN88US=>NXLmToJbW0GQR1XS
AN3-CANUTrUpNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jnXGlEPTB;OT60OVQ1PCEQvF2=NF7jOHZUSU6JRWK=
SK-N-DZMljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DGbWlEPTB;OT63Nlg1QSEQvF2=M2HjN3NCVkeHUh?=
HSC-2Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3DTWM2OD17Lke2OlI6KM7:TR?=Moi1V2FPT0WU
EW-1Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoO5TWM2OD17Lke5N|Y6KM7:TR?=MV7TRW5ITVJ?
D-566MGNED1cFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\mcGlEPTB;OT64N|Y3PCEQvF2=NYXq[4w2W0GQR1XS
COLO-792NGfIVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXJVndLUUN3ME25Mlk5PzR4IN88US=>M2G4b3NCVkeHUh?=
TE-10NGTu[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH64c2NKSzVyPUGwMlA{QTZizszNM3zIfXNCVkeHUh?=
NCI-H650Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2K3[2lEPTB;MUCuOFI5PiEQvF2=NFrObmFUSU6JRWK=
U-266NVXMVpB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2X6d2lEPTB;MUCuOFU2KM7:TR?=Mor4V2FPT0WU
Detroit562NIHqOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlS1TWM2OD1zMT6wOVE2KM7:TR?=M1\PS3NCVkeHUh?=
NH-12MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTFzLkG0OFYh|ryPMmW4V2FPT0WU
CO-314NF2yd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3n[Io2UUN3ME2xNU4zQDR{IN88US=>MYPTRW5ITVJ?
IST-MEL1NIjxW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\Gb2lEPTB;MUGuOVMzOyEQvF2=MmXjV2FPT0WU
KNS-81-FDMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTFzLkW1Nlch|ryPMXvTRW5ITVJ?
SW1463NH;3XZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LtTGlEPTB;MUGuOVk5QSEQvF2=NFf6VnVUSU6JRWK=
NCI-H23NYCyem5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUH4N45OUUN3ME2xNU43PTV{IN88US=>M3K3UHNCVkeHUh?=
SK-MEL-2M3XSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjtNmxlUUN3ME2xNU44OTl5IN88US=>M2\IR3NCVkeHUh?=
NB13NIrIO41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTF{LkG0PVUh|ryPM1nROnNCVkeHUh?=
DaoyMmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjRW25KSzVyPUGyMlI5PTZizszNMYfTRW5ITVJ?
NCI-H1623M{n1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHniRYtKSzVyPUGyMlM5ODFizszNNFrRTG5USU6JRWK=
NMC-G1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVe2eXJLUUN3ME2xNk44OTdizszNNGn1N3JUSU6JRWK=
DK-MGNHWzc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzmVnR1UUN3ME2xNk46PDh{IN88US=>M1vXR3NCVkeHUh?=
TCCSUPNFfkWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfZTWM2OD1zMz6xNlg1KM7:TR?=NGPyWodUSU6JRWK=
SCC-15NYTs[mhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33aZWlEPTB;MUOuNlY2OSEQvF2=NVjTcFZUW0GQR1XS
NOS-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4L1eGlEPTB;MUOuNlg6OyEQvF2=NXmxb5l5W0GQR1XS
RH-1Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInEXYdKSzVyPUGzMlMxOzdizszNMnnNV2FPT0WU
SK-MEL-3MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlizTWM2OD1zMz6zO|I5KM7:TR?=NWfIWXhMW0GQR1XS
NB5MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PxPWlEPTB;MUOuOFA3PyEQvF2=M2DhcHNCVkeHUh?=
SNU-387MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTF|LkWwO|Ih|ryPMVrTRW5ITVJ?
CAL-120NIXIWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDJdGNKSzVyPUGzMlY4OThizszNM3SyfnNCVkeHUh?=
Mo-TNInTRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIq0cmVKSzVyPUGzMlcxPyEQvF2=NXG2enJ5W0GQR1XS
LNCaP-Clone-FGCNGrHboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLVUG5zUUN3ME2xN{44QTl{IN88US=>NYraZXM4W0GQR1XS
CANMkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\oTWM2OD1zND6wNlg5KM7:TR?=MWPTRW5ITVJ?
SK-MEL-30Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojjTWM2OD1zND6wOlMh|ryPMorXV2FPT0WU
COLO-678NEL5[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIe5W2NKSzVyPUG0MlA5OjJizszNMUDTRW5ITVJ?
SCC-9NF6wbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2raUGlEPTB;MUSuNVAzOSEQvF2=NIToXYtUSU6JRWK=
KINGS-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTF2LkG0NFIh|ryPMYLTRW5ITVJ?
SL-513MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfRPVZKSzVyPUG0MlE5PyEQvF2=MVrTRW5ITVJ?
HLEMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLKOWNEUUN3ME2xOE4{QDV{IN88US=>Ml\XV2FPT0WU
SW1573NF;sN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXrU5k{UUN3ME2xOE41PDN3IN88US=>NF3SRWtUSU6JRWK=
KYSE-140NX\ENHdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1O3S2lEPTB;MUSuOlMzPyEQvF2=NIHaelBUSU6JRWK=
SK-PN-DWMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXpTWM2OD1zND64NFAyKM7:TR?=M1j1O3NCVkeHUh?=
A253M1nj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDtTWM2OD1zNT6wOlI2KM7:TR?=M3j5UHNCVkeHUh?=
CAL-12TNHSxPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zSWGlEPTB;MUWuOFY3OiEQvF2=NH3tUIhUSU6JRWK=
COLO-679NVPTS2tGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37RXmlEPTB;MUWuO|Y5OyEQvF2=M3;kbXNCVkeHUh?=
UACC-257NFO1PFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnSR2xKSzVyPUG2MlEzODFizszNNWrRU2ZYW0GQR1XS
U-87-MGNWX3V25UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3IbnBKSzVyPUG2MlM2OjNizszNMUTTRW5ITVJ?
HCC1806M2Gxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\jeWlEPTB;MU[uO|A4OSEQvF2=NXXqNmdUW0GQR1XS
NCI-H2170M{\LRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPufFZ5UUN3ME2xO{4zPDR6IN88US=>M3nDSHNCVkeHUh?=
AGSNYTJ[4kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfvcmxKSzVyPUG3MlM5ODhizszNNYDmXm5DW0GQR1XS
MEL-HOM4TSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTF5Lke1NFMh|ryPM2\B[XNCVkeHUh?=
SW48MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\UTWM2OD1zNz63O|E3KM7:TR?=MYPTRW5ITVJ?
HuP-T4NWHRZlR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTlO29oUUN3ME2xPE4xOjB4IN88US=>MVnTRW5ITVJ?
NCI-H720MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTF6LkG0NFIh|ryPM3LL[XNCVkeHUh?=
RCC10RGBNWXmTlNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\OSGlEPTB;MUiuNVY6PyEQvF2=MnXZV2FPT0WU
HD-MY-ZM4nDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITMWYRKSzVyPUG4MlIzPTRizszNMWXTRW5ITVJ?
A427M{TxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPpXGdPUUN3ME2xPE42ODl2IN88US=>M1fxbXNCVkeHUh?=
HCC2998MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrlc3VKSzVyPUG4MlYxPTFizszNMm\JV2FPT0WU
EPLC-272HMlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPsTWM2OD1zOT6wOFM1KM7:TR?=NULGOHF{W0GQR1XS
C32MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTF7LkC0OUDPxE1?NVS0RXhQW0GQR1XS
UMC-11NIjkc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPwbWVKSzVyPUG5MlIyOjNizszNNF\TO|BUSU6JRWK=
CaR-1M1iyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DIWWlEPTB;MUmuOlgxPCEQvF2=Ml7EV2FPT0WU
KYSE-410NYKxZVE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTF7LkmxN|kh|ryPM4HDOXNCVkeHUh?=
HuCCT1MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTJyLk[yPVQh|ryPMlP0V2FPT0WU
LB996-RCCM1mwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXOcVFKSzVyPUKwMlcyPjhizszNMWjTRW5ITVJ?
KYSE-70NW\YdJUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jEbWlEPTB;MkCuPFA2QSEQvF2=MoXWV2FPT0WU
CAL-72M4HMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXBTWM2OD1{MD65NVUh|ryPNIfSW3RUSU6JRWK=
Capan-2M33Memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTJzLkC0NVMh|ryPMkLKV2FPT0WU
PANC-08-13M2L2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTUTWM2OD1{MT6yOVE2KM7:TR?=MUHTRW5ITVJ?
SBC-1M3v2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vUU2lEPTB;MkGuN|A5OSEQvF2=Mn34V2FPT0WU
MFM-223NHnGXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTsTWM2OD1{MT6zN|QzKM7:TR?=NFLlWnVUSU6JRWK=
BB49-HNCMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTJzLkW3NVYh|ryPM1fvUnNCVkeHUh?=
SH-4NH7tdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfFTWM2OD1{MT62OlE5KM7:TR?=MX\TRW5ITVJ?
HuO9MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoT2TWM2OD1{MT65PFI2KM7:TR?=M{PQUHNCVkeHUh?=
AM-38M4K0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnWxTWM2OD1{Mj6wOFg2KM7:TR?=NG\kT4xUSU6JRWK=
A431MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;SVnVKSzVyPUKzMlIyOTlizszNM125NHNCVkeHUh?=
YAPCNELQd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXUTWM2OD1{Mz6yOlUyKM7:TR?=NFnmfFNUSU6JRWK=
LU-139NG\DVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTJ|LkS4NFkh|ryPNF34PW1USU6JRWK=
HEC-1NHnR[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{Kx[mlEPTB;MkOuOFk{PyEQvF2=MUjTRW5ITVJ?
SCC-25NETRfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTJ2LkOwNFYh|ryPNWfNeYR2W0GQR1XS
HT-29NWTQboFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnmwTWM2OD1{ND6zPFI{KM7:TR?=M{Xhe3NCVkeHUh?=
PC-14MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTJ2Lk[1O|Eh|ryPMoXHV2FPT0WU
Calu-6M1LwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHFVY9EUUN3ME2yOU42ODdzIN88US=>M3fjO3NCVkeHUh?=
SJRH30MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;iNmxKSzVyPUK1MlY1QTZizszNMV3TRW5ITVJ?
ChaGo-K-1NWmyblc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLxTWM2OD1{Nj6xOlI6KM7:TR?=NGHVV4JUSU6JRWK=
IA-LMM3zFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm[wTWM2OD1{Nj6zOlQ2KM7:TR?=M{HGUXNCVkeHUh?=
GP5dMlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjEW45mUUN3ME2yOk41PDlzIN88US=>Mn\DV2FPT0WU
NCI-H2291NWXMbI5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfjXHRKSzVyPUK2MlY2PDFizszNNWTUeY1wW0GQR1XS
BALL-1MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTJ4LkmzPVch|ryPMUfTRW5ITVJ?
HCC1954MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTzVHNuUUN3ME2yOk46QDB6IN88US=>MUfTRW5ITVJ?
NCI-H2452MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzFNmJ5UUN3ME2yO{41OTZ|IN88US=>MonBV2FPT0WU
LU-99AM3W5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPOc2Q2UUN3ME2yO{42PTh{IN88US=>MVXTRW5ITVJ?
NTERA-S-cl-D1MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnRXI1PUUN3ME2yO{44Ojl7IN88US=>M{TNZXNCVkeHUh?=
PANC-10-05MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DP[GlEPTB;MkeuO|c4PSEQvF2=MUDTRW5ITVJ?
NCI-H2405NIr0PZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTJ5LkmzPFch|ryPNV;WfVV5W0GQR1XS
MDA-MB-415Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\5TWM2OD1{OD60NVM4KM7:TR?=M4L2dnNCVkeHUh?=
NCI-H2342M3jhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzKXGxkUUN3ME2yPE42OjhzIN88US=>MXLTRW5ITVJ?
TGBC24TKBM3T1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXsTWM2OD1{OD63NVE4KM7:TR?=NVK0VIdHW0GQR1XS
LU-134-AM4[4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTJ6LkmyOlEh|ryPM2m0WnNCVkeHUh?=
SCC-4M1vXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mln3TWM2OD1|MT6wOFk1KM7:TR?=MVHTRW5ITVJ?
Saos-2MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEOxVGdKSzVyPUOxMlk{ODZizszNM4Xyd3NCVkeHUh?=
RERF-LC-MSNHy5eGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonmTWM2OD1|Mj64NlMyKM7:TR?=NXvoVWZiW0GQR1XS
M14MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXqSlVWUUN3ME2zNk46PzZ2IN88US=>M1\jSnNCVkeHUh?=
HPAF-IINX7jPWc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrzfo1KSzVyPUOzMlUxOTFizszNMn;UV2FPT0WU
NCI-H1755M1PLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DCSmlEPTB;M{SuN|MxPSEQvF2=NIS4W2lUSU6JRWK=
D-392MGMoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTN3Lki2O|Qh|ryPNWHGfW1yW0GQR1XS
A704M1LlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPIfnNKSzVyPUO2MlA1OjdizszNNXz1[ZRyW0GQR1XS
CP50-MEL-BNH[4NYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrFTWM2OD1|Nj6xPVEyKM7:TR?=NX2xdYJZW0GQR1XS
EW-18M1izRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;qTWM2OD1|Nj60OVIh|ryPNFHUO5JUSU6JRWK=
WM-115NIOzU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fCTWlEPTB;M{[uPFA6QSEQvF2=NEXlVm9USU6JRWK=
LU-65MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\ndIFKSzVyPUO3MlE1OTdizszNNIL2SZZUSU6JRWK=
NCI-H1563NXfQV3B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjhUI9KSzVyPUO3MlI1QDRizszNNGSyOJhUSU6JRWK=
DBTRG-05MGNGX2cYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoK3TWM2OD1|OD6wOlkyKM7:TR?=MmD5V2FPT0WU
NCI-H630MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGG0U|FKSzVyPUO4MlQ4OTRizszNNHv5eIhUSU6JRWK=
NCI-H1155NELLb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvLTWM2OD1|OT6yOFIh|ryPMnjKV2FPT0WU
OVACR-3MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DkfGlEPTB;M{muPVE6PSEQvF2=MlnQV2FPT0WU
OAW-42MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTRyLkSyOVgh|ryPNWDpbJNRW0GQR1XS
JVM-2NWnxTZFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXf3TVl{UUN3ME20NU4zPDF3IN88US=>NFPBTmJUSU6JRWK=
C3AM{XyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7ITGpKSzVyPUSxMlM1PDdizszNM2rSb3NCVkeHUh?=
HT55MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfwVJpDUUN3ME20Nk4zQDRzIN88US=>MlTxV2FPT0WU
OVCAR-4MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXGVWFIUUN3ME20Nk4zQTd2IN88US=>NHPhR45USU6JRWK=
MEG-01NGS3OFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4e2XmlEPTB;NEKuOFYyPiEQvF2=M{DSOXNCVkeHUh?=
NCI-H82MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHzXFNKSzVyPUSzMlk5QTJizszNMWrTRW5ITVJ?
JEG-3MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTR2Lkm0O{DPxE1?MUTTRW5ITVJ?
BPH-1NGn5[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfDUWM4UUN3ME20Ok4{QTl6IN88US=>M4fEb3NCVkeHUh?=
MPP-89MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTR5LkK4PVgh|ryPM3ixT3NCVkeHUh?=
ALL-PONHXn[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHzNHhKSzVyPUS3MlQyQDhizszNM3HZXHNCVkeHUh?=
HTM3TUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXFfFVYUUN3ME20O{41QTJizszNM2jrdXNCVkeHUh?=
NCI-H2347NHXuR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fkeGlEPTB;NEiuNFcyPSEQvF2=MW\TRW5ITVJ?
A2780NV\hXlNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnydZpKSzVyPUS5MlQzOjhizszNNY[4bm81W0GQR1XS
KARPAS-299NVzsVWRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfVW3g1UUN3ME20PU42OTF7IN88US=>NW[2R5FSW0GQR1XS
NCI-H1651M4Lrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\wUnFXUUN3ME20PU45QDJzIN88US=>MX\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Protocol(Only for Reference)

Kinase Assay: [1]

Cdk Assays A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.

Cell Assay: [1]

Cell lines Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
Concentrations 0.01-1 μM
Incubation Time 24 hours
Method Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.

Animal Study: [1]

Animal Models Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
Formulation Dissolved in sodium lactate buffer (50 mM, pH 4.0)
Dosages 0-150 mg/kg
Administration Given by gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Fry DW, et al. Mol Cancer Ther, 2004, 3(11), 1427-1438.

[2] Menu E, et al. Cancer Res, 2008, 68(14), 5519-5523.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02730429 Not yet recruiting Endometrial Cancer Nordic Society for Gynaecologic Oncology|ENGOT|GCIG August 2016 Phase 2
NCT02778685 Not yet recruiting Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Recurrent Breast Carcinoma|Stage IV Breast Cancer City of Hope Medical Center|National Cancer Institute (NCI) July 2016 Phase 2
NCT02738866 Not yet recruiting Metastatic Breast Cancer Sidney Kimmel Comprehensive Cancer Center|Pfizer July 2016 Phase 2
NCT02668666 Recruiting Hormone Receptor Positive Malignant Neoplasm of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Estrogen Receptor Positive Brea  ...more Hormone Receptor Positive Malignant Neoplasm of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Estrogen Receptor Positive Breast Cancer|Progesterone Receptor Positive Tumor|Metastatic Breast Cancer Oana Danciu, MD|Pfizer|Hoosier Cancer Research Network|Bi  ...more Oana Danciu, MD|Pfizer|Hoosier Cancer Research Network|Big Ten Cancer Research Consortium June 2016 Phase 2
NCT02806050 Not yet recruiting Breast Cancer University Medical Center Groningen June 2016 Phase 2

view more

Chemical Information

Download Palbociclib (PD-0332991) HCl SDF
Molecular Weight (MW) 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL warming (6.19 mM)
Water 30 mg/mL (61.98 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo Saline 20 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 6-acetyl-8-cyclopentyl-5-methyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one hydrochloride

Customer Product Validation(6)


Click to enlarge
Rating
Source Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck
Method Western Blot/Growth assay
Cell Lines OE33/OE19/Flo1A cells
Concentrations 125 nM
Incubation Time 1/3/21 day
Results PD-0332991 reduces expression of cyclinA in all 3 cell lines. PD-0332991 has no effect on the expression level of either total pRB or RB2 (p130) in EAC cells. PD-0332991 caused a significant reduction in colony formation in soft agar in all 3 cell lines tested, indicative of a reduction in anchorage independence.

Click to enlarge
Rating
Source Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck
Method Immunofluorescence
Cell Lines Patient tumor cell
Concentrations 3 uM
Incubation Time
Results Tumor organoids treated with VPA/ PD0332991 or SAHA/PD0332991 exhibited reduced structural integrity and increased cellular scatter with increasing concentrations of the drugs.

Click to enlarge
Rating
Source Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck
Method Immunofluorescence
Cell Lines Murine MSCs cells
Concentrations 2 uM
Incubation Time 24-48 h
Results We show that when cells are treated with PD332991 for 24–48 h there is a marked decrease in nuclear expression of cdk4 in PAX7- FKHR-expressing mMSCs. Further analysis by immunofluorescence showed that there is a minor upregulation in expression of MyoD1 in cells treated with cdk4 inhibitor for 48 h.

Click to enlarge
Rating
Source Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck
Method Western blot
Cell Lines WM3734 melanoma cells
Concentrations 0.25-4 μM
Incubation Time 36 h
Results

Click to enlarge
Rating
Source Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck
Method Western blot
Cell Lines T98G glioma cells
Concentrations 1 μM
Incubation Time
Results

Click to enlarge
Rating
Source Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck
Method IB analysis, Quantification of soft agar assays
Cell Lines LN319 cells
Concentrations
Incubation Time
Results

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related CDK Products

  • SU9516

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol (Alvocidib) HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

  • LY2835219

    LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Recently Viewed Items

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us